Annuncio pubblicitario
Italia markets open in 2 hours 38 minutes
  • Dow Jones

    38.612,24
    +48,44 (+0,13%)
     
  • Nasdaq

    15.580,87
    -49,91 (-0,32%)
     
  • Nikkei 225

    38.884,13
    +621,97 (+1,63%)
     
  • EUR/USD

    1,0837
    +0,0014 (+0,13%)
     
  • Bitcoin EUR

    47.558,46
    -475,80 (-0,99%)
     
  • CMC Crypto 200

    885,54
    0,00 (0,00%)
     
  • HANG SENG

    16.544,76
    +41,66 (+0,25%)
     
  • S&P 500

    4.981,80
    +6,29 (+0,13%)
     

LifeStance Reports Second Quarter 2023 Results

LifeStance Health, Inc.
LifeStance Health, Inc.

SCOTTSDALE, Ariz., Aug. 09, 2023 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2023.

(All results compared to prior-year comparative period, unless otherwise noted)
Q2 2023 Highlights and FY 2023 Outlook

  • Total revenue of $259.6 million increased $50.1 million or 24% compared to total revenue of $209.5 million

  • Total clinicians of 6,132 up 17%, a sequential net increase of 171 in the second quarter

  • Net loss of $45.5 million compared to net loss of $68.7 million, primarily driven by stock-based compensation expense

  • Adjusted EBITDA of $14.1 million compared to Adjusted EBITDA of $14.6 million

  • Raising revenue and Center Margin guidance: Now expecting full year 2023 revenue of $1.01 to $1.04 billion and Center Margin of $280 to $300 million; reaffirming full year 2023 Adjusted EBITDA guidance of $50 to $62 million

“In the first half of the year, we made solid progress toward execution of our long-term goals,” said Ken Burdick, Chairman and CEO of LifeStance. “In addition to continued operational improvements, we rolled out a new companywide outcomes-informed care program that will highlight the great work that our clinicians do in caring for our patients. LifeStance’s size and scale uniquely positions us to measure quality and outcomes in a disciplined way, and we are excited about this step on our journey to using data and analytics to better inform care and enhance mental health treatment.”

Financial Highlights

 

 

 

 

 

 

 

 

 

 

 

Q2 2023

 

 

Q2 2022

 

 

Y/Y

 

(in millions)

 

 

 

 

 

 

 

 

 

Total revenue

 

$

259.6

 

 

$

209.5

 

 

 

24

%

Loss from operations

 

 

(48.4

)

 

 

(60.5

)

 

 

(20

%)

Center Margin

 

 

73.0

 

 

 

59.8

 

 

 

22

%

Net loss

 

 

(45.5

)

 

 

(68.7

)

 

 

(34

%)

Adjusted EBITDA

 

 

14.1

 

 

 

14.6

 

 

 

(3

%)

As % of Total revenue:

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(18.6

%)

 

 

(28.9

%)

 

 

 

Center Margin

 

 

28.1

%

 

 

28.5

%

 

 

 

Net loss

 

 

(17.5

%)

 

 

(32.8

%)

 

 

 

Adjusted EBITDA

 

 

5.4

%

 

 

7.0

%

 

 

 

(All results compared to prior-year period, unless otherwise noted)

  • Total revenue grew 24% to $259.6 million. Strong revenue growth in the second quarter was driven primarily by net clinician growth and increased visit volumes.

  • Loss from operations was $48.4 million, primarily driven by stock-based compensation expense of $33.1 million. Net loss was $45.5 million.

  • Center Margin grew 22% to $73.0 million, or 28.1% of total revenue.

  • Adjusted EBITDA declined 3% to $14.1 million, or 5.4% of total revenue. Adjusted EBITDA as a percentage of revenue decreased as a result of higher G&A expenses from investments in the business.

Balance Sheet, Cash Flow and Capital Allocation

For the six months ended June 30, 2023, LifeStance used $8.3 million cash flow from operations, including $0.4 million during the second quarter of 2023. The Company ended the second quarter with cash of $79.6 million and net long-term debt of $248.7 million.

2023 Guidance

LifeStance is raising full year revenue and Center Margin guidance, with the following outlook for 2023:

  • The Company expects full year revenue of $1.01 to $1.04 billion, Center Margin of $280 to $300 million, and Adjusted EBITDA of $50 to $62 million.

  • For the third quarter of 2023, the Company expects total revenue of $250 to $260 million, Center Margin of $69 to $76 million, and Adjusted EBITDA of $11 to $17 million.

Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, August 9, 2023, at 8:30 a.m. Eastern Time to discuss the second quarter 2023 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 7177364 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance employs approximately 6,100 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 34 states and approximately 600 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to: full year and third quarter guidance and management's related assumptions; the Company’s financial position; business plans and objectives; expense optimization and other cost-saving initiatives; general economic and industry trends; operating results; working capital and liquidity; and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as “may,” “will,” “should,” “could,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with affiliated practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; the impact of health care reform legislation and other changes in the healthcare industry and in health care spending on us is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our ability to successfully execute on expense optimization initiatives; actual or anticipated changes or fluctuations in our results of operations; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net loss or loss from operations.

Center Margin and Adjusted EBITDA anticipated for the third quarter of 2023 and full year 2023 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking third quarter of 2023 and full year 2023 Center Margin and Adjusted EBITDA guidance is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

Consolidated Financial Information and Reconciliations

CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except for par value)

 

 

 

June 30, 2023

 

 

December 31, 2022

 

CURRENT ASSETS

 

 

 

 

 

 

Cash and cash equivalents

 

$

79,605

 

 

$

108,621

 

Patient accounts receivable, net

 

 

121,796

 

 

 

100,868

 

Prepaid expenses and other current assets

 

 

36,480

 

 

 

23,734

 

Total current assets

 

 

237,881

 

 

 

233,223

 

NONCURRENT ASSETS

 

 

 

 

 

 

Property and equipment, net

 

 

193,144

 

 

 

194,189

 

Right-of-use assets

 

 

191,381

 

 

 

199,431

 

Intangible assets, net

 

 

243,788

 

 

 

263,294

 

Goodwill

 

 

1,293,502

 

 

 

1,272,939

 

Other noncurrent assets

 

 

11,221

 

 

 

10,795

 

Total noncurrent assets

 

 

1,933,036

 

 

 

1,940,648

 

Total assets

 

$

2,170,917

 

 

$

2,173,871

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

Accounts payable

 

$

8,044

 

 

$

12,285

 

Accrued payroll expenses

 

 

81,144

 

 

 

75,650

 

Other accrued expenses

 

 

34,348

 

 

 

30,428

 

Current portion of contingent consideration

 

 

10,537

 

 

 

15,876

 

Operating lease liabilities, current

 

 

43,446

 

 

 

38,824

 

Other current liabilities

 

 

3,335

 

 

 

2,936

 

Total current liabilities

 

 

180,854

 

 

 

175,999

 

NONCURRENT LIABILITIES

 

 

 

 

 

 

Long-term debt, net

 

 

248,718

 

 

 

225,079

 

Operating lease liabilities, noncurrent

 

 

205,586

 

 

 

212,586

 

Deferred tax liability, net

 

 

38,324

 

 

 

38,701

 

Other noncurrent liabilities

 

 

2,559

 

 

 

2,783

 

Total noncurrent liabilities

 

 

495,187

 

 

 

479,149

 

Total liabilities

 

$

676,041

 

 

$

655,148

 

COMMITMENTS AND CONTINGENCIES

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Preferred stock – par value $0.01 per share; 25,000 shares authorized as of June 30, 2023 and December 31, 2022; 0 shares issued and outstanding as of June 30, 2023 and December 31, 2022

 

 

 

 

 

 

Common stock – par value $0.01 per share; 800,000 shares authorized as of June 30, 2023 and December 31, 2022; 378,005 and 375,964 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

 

 

3,782

 

 

 

3,761

 

Additional paid-in capital

 

 

2,141,247

 

 

 

2,084,324

 

Accumulated other comprehensive income

 

 

4,151

 

 

 

3,274

 

Accumulated deficit

 

 

(654,304

)

 

 

(572,636

)

Total stockholders' equity

 

 

1,494,876

 

 

 

1,518,723

 

Total liabilities and stockholders’ equity

 

$

2,170,917

 

 

$

2,173,871

 




CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(In thousands, except for Net Loss per Share)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

TOTAL REVENUE

 

$

259,578

 

 

$

209,527

 

 

$

512,167

 

 

$

412,622

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

Center costs, excluding depreciation and
amortization shown separately below

 

 

186,607

 

 

 

149,697

 

 

 

369,594

 

 

 

298,590

 

General and administrative expenses

 

 

101,854

 

 

 

103,559

 

 

 

186,480

 

 

 

206,928

 

Depreciation and amortization

 

 

19,530

 

 

 

16,743

 

 

 

38,599

 

 

 

32,427

 

Total operating expenses

 

$

307,991

 

 

$

269,999

 

 

$

594,673

 

 

$

537,945

 

LOSS FROM OPERATIONS

 

$

(48,413

)

 

$

(60,472

)

 

$

(82,506

)

 

$

(125,323

)

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

 

 

 

 

 

Gain (loss) on remeasurement of
contingent consideration

 

 

1,539

 

 

 

(180

)

 

 

2,576

 

 

 

(614

)

Transaction costs

 

 

(3

)

 

 

(19

)

 

 

(89

)

 

 

(297

)

Interest expense, net

 

 

(5,119

)

 

 

(7,133

)

 

 

(10,211

)

 

 

(10,574

)

Other expense

 

 

(24

)

 

 

 

 

 

(69

)

 

 

 

Total other expense

 

$

(3,607

)

 

$

(7,332

)

 

$

(7,793

)

 

$

(11,485

)

LOSS BEFORE INCOME TAXES

 

 

(52,020

)

 

 

(67,804

)

 

 

(90,299

)

 

 

(136,808

)

INCOME TAX BENEFIT (PROVISION)

 

 

6,542

 

 

 

(923

)

 

 

10,579

 

 

 

5,753

 

NET LOSS

 

$

(45,478

)

 

$

(68,727

)

 

$

(79,720

)

 

$

(131,055

)

NET LOSS PER SHARE, BASIC AND DILUTED

 

 

(0.13

)

 

 

(0.19

)

 

 

(0.22

)

 

 

(0.37

)

Weighted-average shares used to compute
basic and diluted net loss per share

 

 

363,161

 

 

 

353,729

 

 

 

362,039

 

 

 

352,297

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS

 

$

(45,478

)

 

$

(68,727

)

 

$

(79,720

)

 

$

(131,055

)

OTHER COMPREHENSIVE INCOME

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gains on cash flow hedge, net of tax

 

 

2,147

 

 

 

 

 

 

877

 

 

 

 

COMPREHENSIVE LOSS

 

$

(43,331

)

 

$

(68,727

)

 

$

(78,843

)

 

$

(131,055

)


CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)

 

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$

(79,720

)

 

$

(131,055

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

38,599

 

 

 

32,427

 

Non-cash operating lease costs

 

 

20,263

 

 

 

 

Stock-based compensation

 

 

56,944

 

 

 

117,365

 

Loss on debt extinguishment

 

 

 

 

 

3,380

 

Amortization of discount and debt issue costs

 

 

1,076

 

 

 

748

 

(Gain) loss on remeasurement of contingent consideration

 

 

(2,576

)

 

 

614

 

Other, net

 

 

2,708

 

 

 

 

Change in operating assets and liabilities, net of businesses acquired:

 

 

 

 

 

 

Patient accounts receivable, net

 

 

(20,558

)

 

 

(21,900

)

Prepaid expenses and other current assets

 

 

(15,176

)

 

 

(5,351

)

Accounts payable

 

 

(5,395

)

 

 

1,731

 

Accrued payroll expenses

 

 

5,158

 

 

 

(289

)

Operating lease liabilities

 

 

(16,929

)

 

 

 

Other accrued expenses

 

 

7,282

 

 

 

13,471

 

Net cash (used in) provided by operating activities

 

$

(8,324

)

 

$

11,141

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

Purchases of property and equipment

 

 

(19,310

)

 

 

(53,775

)

Acquisitions of businesses, net of cash acquired

 

 

(19,820

)

 

 

(35,118

)

Net cash used in investing activities

 

$

(39,130

)

 

$

(88,893

)

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

Proceeds from long-term debt, net of discount

 

 

25,000

 

 

 

228,000

 

Payments of debt issue costs

 

 

(188

)

 

 

(7,184

)

Payments of long-term debt

 

 

(1,173

)

 

 

(181,230

)

Prepayment for debt paydown

 

 

 

 

 

(1,609

)

Payments of contingent consideration

 

 

(5,201

)

 

 

(11,090

)

Taxes related to net share settlement of equity awards

 

 

 

 

 

(478

)

Net cash provided by financing activities

 

$

18,438

 

 

$

26,409

 

NET DECREASE IN CASH AND CASH EQUIVALENTS

 

 

(29,016

)

 

 

(51,343

)

Cash and Cash Equivalents - Beginning of period

 

 

108,621

 

 

 

148,029

 

CASH AND CASH EQUIVALENTS – END OF PERIOD

 

$

79,605

 

 

$

96,686

 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

 

 

 

 

 

 

Cash paid for interest, net

 

$

9,830

 

 

$

4,927

 

Cash paid for taxes, net of refunds

 

$

313

 

 

$

860

 

SUPPLEMENTAL DISCLOSURES OF NON CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

Equipment financed through finance leases

 

$

 

 

$

256

 

Contingent consideration incurred in acquisitions of businesses

 

$

1,985

 

 

$

5,683

 

Acquisition of property and equipment included in liabilities

 

$

6,238

 

 

$

13,055

 



RECONCILIATION OF LOSS FROM OPERATIONS TO CENTER MARGIN

(unaudited)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

$

(48,413

)

 

$

(60,472

)

 

$

(82,506

)

 

$

(125,323

)

Adjusted for:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

19,530

 

 

 

16,743

 

 

 

38,599

 

 

 

32,427

 

General and administrative expenses (1)

 

 

101,854

 

 

 

103,559

 

 

 

186,480

 

 

 

206,928

 

Center Margin

 

$

72,971

 

 

$

59,830

 

 

$

142,573

 

 

$

114,032

 

(1)    Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-based compensation for all employees.


RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA

(unaudited)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(45,478

)

 

$

(68,727

)

 

$

(79,720

)

 

$

(131,055

)

Adjusted for:

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

5,119

 

 

 

7,133

 

 

 

10,211

 

 

 

10,574

 

Depreciation and amortization

 

 

19,530

 

 

 

16,743

 

 

 

38,599

 

 

 

32,427

 

Income tax (benefit) provision

 

 

(6,542

)

 

 

923

 

 

 

(10,579

)

 

 

(5,753

)

(Gain) loss on remeasurement of
contingent consideration

 

 

(1,539

)

 

 

180

 

 

 

(2,576

)

 

 

614

 

Stock-based compensation expense

 

 

33,078

 

 

 

57,510

 

 

 

56,944

 

 

 

117,365

 

Loss on disposal of assets

 

 

24

 

 

 

 

 

 

69

 

 

 

 

Transaction costs (1)

 

 

3

 

 

 

19

 

 

 

89

 

 

 

297

 

Executive transition costs

 

 

362

 

 

 

 

 

 

522

 

 

 

 

Litigation costs (2)

 

 

3,446

 

 

 

 

 

 

3,849

 

 

 

 

Strategic initiatives (3)

 

 

2,045

 

 

 

 

 

 

2,452

 

 

 

 

Special charges (4)

 

 

3,720

 

 

 

 

 

 

3,720

 

 

 

 

Other expenses (5)

 

 

297

 

 

 

851

 

 

 

589

 

 

 

2,645

 

Adjusted EBITDA

 

$

14,065

 

 

$

14,632

 

 

$

24,169

 

 

$

27,114

 

(1)    Primarily includes capital markets advisory, consulting, accounting and legal expenses related to our acquisitions.
(2)    Litigation costs include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case, (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy.
(3)    Represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to our systems strategic initiatives.
(4)    Special charges include certain asset impairment costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization project to consolidate our physical footprint.
(5)    Primarily includes costs incurred to consummate or integrate acquired centers, certain of which are wholly-owned and certain of which are affiliated practices, in addition to the compensation paid to former owners of acquired centers and related expenses that are not reflective of the ongoing operating expenses of our centers. Acquired center integration and other are components of general and administrative expenses included in our unaudited consolidated statements of operations and comprehensive loss. Former owner fees is a component of center costs, excluding depreciation and amortization included in our unaudited consolidated statements of operations and comprehensive loss.

CONTACT: Investor Relations Contact Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com